Ignite Creation Date:
2024-05-05 @ 4:37 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00282932
Status:
COMPLETED
Last Update Posted:
2021-01-27
First Post:
2006-01-26
Brief Title:
Detrol LA In Men With Overactive Bladder
Sponsor:
Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization:
Pfizer
Study Overview
Official Title:
A Randomized Double Blind Placebo Controlled Detrol LA Add-On To Alpha-Blocker Study In Men With Persistent Overactive Bladder Symptoms Of Urinary Frequency And Urgency WithWithout Urgency Incontinence After Previous Monotherapy With Alpha Blocker
Status:
COMPLETED
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An interventional activeplacebo double blinded parallel randomized controlled study in which at 12 weeks of treatment the primary endpoint of patient perception of bladder condition is measured along with associated safety and other secondary endpoints like bladder diary endpoints quality of life and patient treatment satisfaction
Patients included in the study must have symptoms of OAB frequency of at least 8 per day and Urgency of at least 1 episode per day confirmed by bladder diary
Patients are not eligible to enroll in the study if they havehad significant hepatic or renal disease history of radiation treatment
Patients included in the study must have symptoms of OAB frequency of at least 8 per day and Urgency of at least 1 episode per day confirmed by bladder diary
Patients are not eligible to enroll in the study if they havehad significant hepatic or renal disease history of radiation treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None